Open Collections

UBC Faculty Research and Publications

Using Framingham for primary prevention cardiovascular risk assessment Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 63 looks at the use of Framingham for primary prevention cardiovascular risk assessment. As with most calculators, family history and weight are not variables and so clinicians must use clinical judgment when these factors are considered important. Conclusions: If you use Framingham to calculate risk, make sure you know what endpoints are included and over what period of time. Framingham risk assessment has a number of limitations and there is a lack of evidence of its impact on prescribing practice or health outcomes. Risk assessment needs to be studied in RCTs as compared to standard care to determine the impact on prescribing in patient populations with different risks at baseline and to see if patients presented with risk estimates feel more informed and make different treatment decisions.

Item Metadata

Title
Using Framingham for primary prevention cardiovascular risk assessment
Alternate Title
Therapeutics Letter 63
Creator
Therapeutics Initiative (University of British Columbia)
Date Issued
2007-04
Description
Therapeutics Letter 63 looks at the use of Framingham for primary prevention cardiovascular risk assessment. As with most calculators, family history and weight are not variables and so clinicians must use clinical judgment when these factors are considered important. Conclusions: If you use Framingham to calculate risk, make sure you know what endpoints are included and over what period of time. Framingham risk assessment has a number of limitations and there is a lack of evidence of its impact on prescribing practice or health outcomes. Risk assessment needs to be studied in RCTs as compared to standard care to determine the impact on prescribing in patient populations with different risks at baseline and to see if patients presented with risk estimates feel more informed and make different treatment decisions.
Subject
Cardiovascular Diseases; Heart Disease Risk Factors; Primary Prevention; Risk Assessment; Risk Factors
Genre
Other
Type
Text
Language
eng
Notes
The UBC TI is funded by the BC Ministry of Health to provide evidence-based information about drug therapy. We neither formulate nor adjudicate provincial drug policies.
Date Available
2023-06-20
Provider
Vancouver : University of British Columbia Library
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
DOI
10.14288/1.0433642
URI
http://hdl.handle.net/2429/85052
Affiliation
Medicine, Faculty of; Anesthesiology, Pharmacology and Therapeutics, Department of
Peer Review Status
Reviewed
Scholarly Level
Faculty; Researcher
Rights URI
http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International